Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. & Medzhitov, R. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 118, 229–241 (2004).
Xu, J. et al. A genomic view of the human-Bacteroides thetaiotaomicron symbiosis. Science 299, 2074–2076 (2003).
Rakoff-Nahoum, S., Hao, L. & Medzhitov, R. Role of Toll-like receptors in spontaneous commensal-dependent colitis. Immunity 25, 319–329 (2006).
Netea, M.G., Van der Meer, J.W. & Kullberg, B.J. Toll-like receptors as an escape mechanism from the host defense. Trends Microbiol. 12, 484–488 (2004).
Kelly, D., Conway, S. & Aminov, R. Commensal gut bacteria: mechanisms of immune modulation. Trends Immunol. 26, 326–333 (2005).
Steidler, L. et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352–1355 (2000).
Vandenbroucke, K. et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 127, 502–513 (2004).
Haller, D. et al. Transforming growth factor-β1 inhibits nonpathogenic Gram negative bacteria–induced NF-κB recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation. J. Biol. Chem. 278, 23851–23860 (2003).
Marshak-Rothstein, A. & Rifkin, I.R. Immunologically active autoantigens: the role of Toll-like receptors in the development of chronic inflammatory disease. Annu. Rev. Immunol. 25, 419–441 (2007).
Leadbetter, E.A. et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603–607 (2002).
Matzinger, P. Tolerance, danger and the extended family. Annu. Rev. Immunol. 12, 991–1045 (1994).
Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6, 823–835 (2006).
Ziebuhr, W. et al. Nosocomial infections by Staphylococcus epidermidis: how a commensal bacterium turns into a pathogen. Int. J. Antimicrob. Agents 28Suppl 1, S14–S20 (2006).
Bibel, D.J. et al. Competitive adherence as a mechanism of bacterial interference. Can. J. Microbiol. 29, 700–703 (1983).
Lebre, M.C. et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J. Invest. Dermatol. 127, 331–341 (2007).
Pivarcsi, A. et al. Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int. Immunol. 15, 721–730 (2003).
Baker, B.S., Ovigne, J.M., Powles, A.V., Corcoran, S. & Fry, L. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br. J. Dermatol. 148, 670–679 (2003).
Alexopoulou, L., Holt, A.C., Medzhitov, R. & Flavell, R.A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413, 732–738 (2001).
Fujimoto, C., Nakagawa, Y., Ohara, K. & Takahashi, H. Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. Int. Immunol. 16, 55–63 (2004).
Cavassani, K.A. et al. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J. Exp. Med. 205, 2609–2621 (2008).
Brown, D.L., Kao, W.W. & Greenhalgh, D.G. Apoptosis down-regulates inflammation under the advancing epithelial wound edge: delayed patterns in diabetes and improvement with topical growth factors. Surgery 121, 372–380 (1997).
Kono, H. & Rock, K.L. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8, 279–289 (2008).
Vanhoutte, F. et al. Toll-like receptor (TLR)2 and TLR3 synergy and cross-inhibition in murine myeloid dendritic cells. Immunol. Lett. 116, 86–94 (2008).
Ghosh, T.K. et al. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-α. Int. Immunopharmacol. 7, 1111–1121 (2007).
Lambert, P.A., Worthington, T., Tebbs, S.E. & Elliott, T.S. Lipid S, a novel Staphylococcus epidermidis exocellular antigen with potential for the serodiagnosis of infections. FEMS Immunol. Med. Microbiol. 29, 195–202 (2000).
Weidenmaier, C. et al. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat. Med. 10, 243–245 (2004).
Kawai, T. & Akira, S. TLR signaling. Semin. Immunol. 19, 24–32 (2007).
Hooper, L.V. Do symbiotic bacteria subvert host immunity? Nat. Rev. Microbiol. 7, 367–374 (2009).
Timmerman, C.P. et al. Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect. Immun. 61, 4167–4172 (1993).
Yoshioka, M. et al. Lipoteichoic acid downregulates FcεRI expression on human mast cells through Toll-like receptor 2. J. Allergy Clin. Immunol. 120, 452–461 (2007).
Han, J. & Ulevitch, R.J. Limiting inflammatory responses during activation of innate immunity. Nat. Immunol. 6, 1198–1205 (2005).
Stack, J. et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med. 201, 1007–1018 (2005).
Harte, M.T. et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J. Exp. Med. 197, 343–351 (2003).
Thompson, A.J. & Locarnini, S.A. Toll-like receptors, RIG-I–like RNA helicases and the antiviral innate immune response. Immunol. Cell Biol. 85, 435–445 (2007).
Szpaderska, A.M. & DiPietro, L.A. Inflammation in surgical wound healing: friend or foe? Surgery 137, 571–573 (2005).
Wetzler, C., Kampfer, H., Stallmeyer, B., Pfeilschifter, J. & Frank, S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J. Invest. Dermatol. 115, 245–253 (2000).
Gründling, A. & Schneewind, O. Synthesis of glycerol phosphate lipoteichoic acid in Staphylococcus aureus. Proc. Natl. Acad. Sci. USA 104, 8478–8483 (2007).
Schauber, J. et al. Histone acetylation in keratinocytes enables control of the expression of cathelicidin and CD14 by 1,25-dihydroxyvitamin D3. J. Invest. Dermatol. 128, 816–824 (2007).
Nizet, V. et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414, 454–457 (2001).